Post by Sachs Associates

Biotechnology executive, entrepreneur, physician-scientist, and board member with deep expertise in drug and device development across longevity science, immunology, dermatology, obesity, rare diseases, and neuroscience. Currently CEO and Director of Rubedo Life Sciences, an AI-enabled clinical-stage biotech focused on age-related diseases, whose lead drug is in Phase 2. It has potential in autoimmune, dermatology, cardiometabolic and neurodegenerative disorders. Founder and board member of Steelhead Therapeutics, a complement therapeutics company and board director at Neurodon. Neurodon is a private near clinical stage biotech company whose lead drug is a novel SERCA activator nearing IND and has potential to treat obesity, diabetes and cardiometabolic diseases. Previously CEO Kira Pharmaceuticals, Sienna Biopharmaceuticals, and held senior R&D leadership roles at Allergan and Kythera, contributing to approvals of major global products including BOTOX, Juvederm, Aczone, Tazorac, Kybella, and Latisse. UCLA faculty member, board-certified dermatologist, and experienced biotech founder with expertise in company formation, fundraising, IPOs, and clinical development. Meet Frederick Beddingfield MD, PhD @ #Sachs_OCIF More Info @ https://lnkd.in/e44tnKf3 #ObesityInnovation #CardiometabolicHealth #MetabolicDiseases #ObesityTreatment #DiabetesCare #GLP1 #CardioMetabolic #LifeSciences #BioPharma #BiotechInvestment #HealthcareInnovation #TherapeuticInnovation #PharmaDeals #BiotechConference #InvestmentOpportunities #MetabolicHealth #NextGenTherapies #ADA2026